{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:15:48Z","timestamp":1774725348497,"version":"3.50.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.contraception.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T07:51:06Z","timestamp":1545119466000},"page":"199-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women"],"prefix":"10.1016","volume":"99","author":[{"given":"Renee","family":"Heffron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laneta J.","family":"Dorflinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet P.","family":"Hapgood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Kiarie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea B.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrus S.","family":"Steyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2018.12.001_bb0005","series-title":"Physician information for depo-subQ provera 104\u00aemedroxyprogesterone acetate injectable suspension 104 mg\/0.65 mL","author":"Pfizer","year":"2013"},{"key":"10.1016\/j.contraception.2018.12.001_bb0010","series-title":"Prescribing information for DEPO-PROVERA CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use","author":"Pfizer","year":"2010"},{"key":"10.1016\/j.contraception.2018.12.001_bb0015","series-title":"Product information for Noristerat 200mg, solution for intramuscular injection","author":"Bayer","year":"2017"},{"key":"10.1016\/j.contraception.2018.12.001_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(12)60478-4","article-title":"Maternal deaths averted by contraceptive use: an analysis of 172 countries","volume":"380","author":"Ahmed","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2018.12.001_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10995-009-0546-2","article-title":"Intention to become pregnant and low birth weight and preterm birth: a systematic review","volume":"15","author":"Shah","year":"2011","journal-title":"Matern Child Health J"},{"key":"10.1016\/j.contraception.2018.12.001_bb0030","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/COH.0b013e3283632bd7","article-title":"The role of family planning in elimination of new pediatric HIV infection","volume":"8","author":"Wilcher","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.contraception.2018.12.001_bb0035","series-title":"Medical eligibility criteria for contraceptive use fifth edition 2015","author":"Human Reproduction Program WHO","year":"2015"},{"key":"10.1016\/j.contraception.2018.12.001_bb0040","series-title":"Department of Reproductive Health and Research. Hormonal contraception and HIV: technical statement","first-page":"2012","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.contraception.2018.12.001_bb0045","author":"World Health Organization"},{"key":"10.1016\/j.contraception.2018.12.001_bb0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.9745\/GHSP-D-17-00278","article-title":"From research to policy: the WHO experience with developing guidelines on the potential risk of HIV acquisition and progestogen-only contraception use","volume":"5","author":"Han","year":"2017","journal-title":"Global Health Sci Pract"},{"key":"10.1016\/j.contraception.2018.12.001_bb0055","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amepre.2005.02.008","article-title":"Keeping up with evidence a new system for WHO's evidence-based family planning guidance","volume":"28","author":"Mohllajee","year":"2005","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.contraception.2018.12.001_bb0060","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/QAD.0000000000001228","article-title":"Update on hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence, 2016","volume":"30","author":"Polis","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2018.12.001_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/infdis\/163.2.233","article-title":"Cofactors in male-female sexual transmission of human immunodeficiency virus type 1","volume":"163","author":"Plummer","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1210\/er.2017-00103","article-title":"Hormonal contraception and HIV-1 acquisition: biological mechanisms","volume":"39","author":"Hapgood","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.contraception.2018.12.001_bb0075","author":"United Nations Population Division"},{"key":"10.1016\/j.contraception.2018.12.001_bb0080","author":"U. S. Food and Drug Administration"},{"key":"10.1016\/j.contraception.2018.12.001_bb0085","series-title":"https:\/\/www.rhsupplies.org\/fileadmin\/uploads\/rhsc\/Tools\/DMPA_Kit\/Files\/DMPA-SC_complete_advocacy_pack_2017.pdf","article-title":"Advocacy pack for subcutaneous DMPA","author":"PATH","year":"2017"},{"key":"10.1016\/j.contraception.2018.12.001_bb0090","author":"WHO Department of Reproductive Health and Research"},{"key":"10.1016\/j.contraception.2018.12.001_bb0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2017.12.003","article-title":"Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?","volume":"97","author":"Polis","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.contraception.2017.09.013","article-title":"Misreporting of contraceptive hormone use in clinical research participants","volume":"97","author":"Achilles","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2018.01.015","article-title":"Simultaneous quantitation of multiple contraceptive hormones in human serum by LC-MS\/MS","volume":"97","author":"Blue","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.contraception.2016.03.003","article-title":"Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial","volume":"94","author":"Nanda","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0010-7824(86)90004-1","volume":"34","author":"Said","year":"1986","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/aji.12214","article-title":"Differential glucocorticoid receptor-mediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis","volume":"71","author":"Hapgood","year":"2014","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2004.11.013","article-title":"Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg\/0.65 mL) contraceptive formulation in Asian women","volume":"26","author":"Toh","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2018.12.001_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2004.01.011","article-title":"Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0135","author":"Food and Drug Administration Center for Drug Evaluation and Research"},{"key":"10.1016\/j.contraception.2018.12.001_bb0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.contraception.2013.10.010","article-title":"Subcutaneous DMPA: a better lower dose approach","volume":"89","author":"Shelton","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.contraception.2009.02.005","article-title":"Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density","volume":"80","author":"Kaunitz","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.contraception.2009.07.007","article-title":"Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception","volume":"81","author":"Beksinska","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(83)80002-X","volume":"28","year":"1983","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005214.pub2","article-title":"Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception","author":"Draper","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2018.12.001_bb0165","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0010-7824(85)90004-6","article-title":"Return to ovulation following the use of long-acting injectable contraceptives: a comparative study","volume":"31","author":"Garza-Flores","year":"1985","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0010-7824(86)80013-0","article-title":"Return of fertility following discontinuation of an injectable contraceptive--norethisterone oenanthate (NET EN) 200mg dose. Council of Medical Research","volume":"34","author":"ICMR (Indian Council of Medical Research) Task Force on Hormonal Contraception","year":"1986","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0010-7824(74)90073-0","article-title":"The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review","volume":"10","author":"Schwallie","year":"1974","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.contraception.2013.11.008","article-title":"Preference for Sayana(R) Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial","volume":"89","author":"Polis","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.contraception.2008.11.009","article-title":"Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate","volume":"79","author":"Beksinska","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0190","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.fertnstert.2004.04.064","article-title":"Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate","volume":"82","author":"Clark","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2018.12.001_bb0195","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1089\/aid.2012.0271","article-title":"Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues","volume":"29","author":"Chandra","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.contraception.2018.12.001_bb0200","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/humrep\/dev035","article-title":"Medroxyprogesterone acetate impairs human dendritic cell activation and function","volume":"30","author":"Quispe Calla","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2018.12.001_bb0205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(15)00429-6","article-title":"Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study","volume":"16","author":"Byrne","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0210","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jiv233","article-title":"CCR5 expression levels in HIV-uninfected women receiving hormonal contraception","volume":"212","author":"Sciaranghella","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu176","article-title":"Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells","author":"Mitchell","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/QAI.0000000000000531","article-title":"Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract","volume":"68","author":"Michel","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2018.12.001_bb0225","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.contraception.2014.01.024","article-title":"Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate","volume":"90","author":"Bahamondes","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0230","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/aji.12415","article-title":"Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract","volume":"74","author":"Deese","year":"2015","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000000533","article-title":"Depot medroxyprogesterone acetate use is associated with elevated innate immune effector molecules in cervicovaginal secretions of HIV-1-uninfected women","volume":"69","author":"Guthrie","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2018.12.001_bb0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jri.2015.03.007","article-title":"Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive","volume":"110","author":"Ngcapu","year":"2015","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0245","doi-asserted-by":"crossref","first-page":"e00221-15","DOI":"10.1128\/mBio.00221-15","article-title":"The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception","volume":"6","author":"Fichorova","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.contraception.2018.12.001_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143109","article-title":"Immune activation in the female genital tract: expression profiles of soluble proteins in women at high risk for HIV infection","volume":"11","author":"Francis","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2018.12.001_bb0255","doi-asserted-by":"crossref","first-page":"622 e1","DOI":"10.1016\/j.ajog.2018.02.017","article-title":"Impact of contraceptive initiation on vaginal microbiota","volume":"281","author":"Achilles","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0260","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.tips.2004.09.005","article-title":"Not all progestins are the same: implications for usage","volume":"25","author":"Hapgood","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.contraception.2018.12.001_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2005.07.001","article-title":"Synthetic progestins used in HRT have different glucocorticoid agonist properties","volume":"242","author":"Koubovec","year":"2005","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.contraception.2018.12.001_bb0275","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.steroids.2011.03.001","article-title":"Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception","volume":"76","author":"Africander","year":"2011","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2018.12.001_bb0280","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jsbmb.2014.05.007","article-title":"A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A)","volume":"143","author":"Africander","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0285","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/0006-2952(83)90474-4","article-title":"Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes","volume":"32","author":"Kontula","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0290","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mce.2008.10.008","article-title":"Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction","volume":"299","author":"Ronacher","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0295","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/jc.2007-0044","article-title":"Formation of ethinyl estradiol in women during treatment with norethindrone acetate","volume":"92","author":"Chu","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.contraception.2018.12.001_bb0300","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1933719112438061","article-title":"The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis","volume":"19","author":"Chwalisz","year":"2012","journal-title":"Reprod Sci"},{"key":"10.1016\/j.contraception.2018.12.001_bb0305","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.contraception.2013.07.002","article-title":"Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm","volume":"89","author":"Halpern","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0310","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2004.03.006","article-title":"Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells","volume":"221","author":"Koubovec","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096497","article-title":"The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor","volume":"9","author":"Govender","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2018.12.001_bb0320","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/en.2012-1850","article-title":"Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms","volume":"154","author":"Huijbregts","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.contraception.2018.12.001_bb0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.contraception.2014.02.006","article-title":"Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs","volume":"90","author":"Huijbregts","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024639","article-title":"Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users","volume":"6","author":"Kleynhans","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2018.12.001_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062895","article-title":"The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor","volume":"8","author":"Tomasicchio","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.contraception.2018.12.001_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196043","article-title":"Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4\/CD8 ratios and CCR5 levels","volume":"13","author":"Maritz","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2018.12.001_bb0345","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/QAD.0000000000000681","article-title":"Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro","volume":"29","author":"Sampah","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2018.12.001_bb0350","first-page":"590","article-title":"Genital injury signatures and microbiome alterations associated with depot medroxyprogesterone acetate usage and intravaginal drying practices","volume":"215","author":"Birse","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0355","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4049\/immunohorizons.1700047","article-title":"Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4(+) T cells to HIV infection","volume":"1","author":"Tasker","year":"2017","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.contraception.2018.12.001_bb0360","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/mi.2016.22","article-title":"Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection","volume":"9","author":"Quispe Calla","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.contraception.2018.12.001_bb0365","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00410-17","article-title":"Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females","volume":"86","author":"Lennard","year":"2018","journal-title":"Infect Immun"},{"key":"10.1016\/j.contraception.2018.12.001_bb0370","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1473-3099(18)30058-6","article-title":"Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study","volume":"18","author":"McClelland","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0375","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.contraception.2016.11.006","article-title":"Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome","volume":"95","author":"Brooks","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073055","article-title":"Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis","volume":"8","author":"Vodstrcil","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2018.12.001_bb0385","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1097\/QAD.0b013e32836290b6","article-title":"Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission","volume":"27","author":"Van de Wijgert","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.contraception.2018.12.001_bb0390","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/infdis\/jiu832","article-title":"Medroxyprogesterone acetate regulates HIV-1 uptake and transcytosis but not replication in primary genital epithelial cells, resulting in enhanced T-cell infection","volume":"211","author":"Ferreira","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0395","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(13)70155-5","article-title":"Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence","volume":"13","author":"Polis","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0400","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.contraception.2014.07.009","article-title":"Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence","volume":"90","author":"Polis","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001778","article-title":"Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis","volume":"12","author":"Morrison","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.contraception.2018.12.001_bb0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(14)71052-7","article-title":"Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies","volume":"15","author":"Ralph","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.contraception.2018.12.001_bb0415","first-page":"129","article-title":"Risk of HIV infection in depot-medroxyprogesterone acetate (DMPA) users: a systematic review and meta-analysis","volume":"30","author":"Brind","year":"2015","journal-title":"Issues Law Med"},{"key":"10.1016\/j.contraception.2018.12.001_bb0420","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/bmj.316.7125.140","article-title":"Spurious precision? Meta-analysis of observational studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2018.12.001_bb0425","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(15)00058-2","article-title":"Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study","volume":"2","author":"Noguchi","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2018.12.001_bb0430","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.contraception.2006.01.005","article-title":"Preferences between injectable contraceptive methods among South African women","volume":"73","author":"Morroni","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2018.12.001_bb0435","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.contraception.2018.01.011","article-title":"Concordance of self-reported hormonal contraceptive use and presence of exogenous hormones in serum among African women","volume":"97","author":"Pyra","year":"2018","journal-title":"Contraception"}],"updated-by":[{"DOI":"10.1016\/j.contraception.2019.05.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000}}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782418305249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782418305249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:22:49Z","timestamp":1654734169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782418305249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0010782418305249"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2018.12.001","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.contraception.2019.05.014","asserted-by":"object"}]},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 World Health Organization; licensee Elsevier Inc.","name":"copyright","label":"Copyright"}]}}